SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: jopawa who wrote (2115)7/22/1998 6:12:00 PM
From: michael i olson  Read Replies (2) | Respond to of 4676
 
Looking at todays activity, the stats shows there was none.
Can anyone explain this?



To: jopawa who wrote (2115)7/22/1998 6:30:00 PM
From: Scott H. Davis  Respond to of 4676
 
John, another dynamic may take place pretty soon. Development stage biotechs are pretty volitle yet news can have seemingly minimal effect. I'm noticing that as a company gets to the place where the market has colectivly determined that the company is going to make it,
the volitility decreases & response to news makes more sense.

Has clearly happened with VICL this year. ISIP may be approaching this with a no restriction antisense approval. IMSCO Scott



To: jopawa who wrote (2115)7/22/1998 8:25:00 PM
From: Scott H. Davis  Read Replies (1) | Respond to of 4676
 
Some additional benefits of the news. While the drug will not generate a lot of $, the cash flow will help fund other development/help avoid share dilution that would result from a secondary placement. Also its a vote of confidence in ISIP management
in their ability to work effectively with the FDA & their NDA submission approach. Big grin time. Scott


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News